ADCT ADC Therapeutics SA Insider Trading

Redmile Group, LLC sells 5,880,415 shares for $19.6M in 6 transactions; holding reduced 36.4%.

Redmile Group, LLC, the company's 10% owner, executed 6 separate sales totaling 5,880,415 shares for $19.6M between March 31 and April 2, 2026, with prices ranging from $3.28 to $3.80 and a blended average of $3.34. This represents a substantial reduction of 36.4% of the insider's pre-transaction holdings (from 16,145,712 to 10,265,297 shares). The stock is currently trading at $3.78 (current price), -22.5% from its 52-week high of $4.88, and has declined 6.7% over the prior 30 days. The company is unprofitable with a most recent quarterly revenue of $16.4M and a full-year net income of $-41.0M, though annual revenue growth stands at 14.8%. At the cross-ticker level, Redmile's 3 prior sells posted an average 90-day return of -20.5% with a well-timed rate of 100.00%; however, at this same ticker (ADCT), Redmile's 5 prior trades (all buys in late 2024) showed only 1 of 5 well-timed at the 90-day mark, with the most recent December 2024 buys declining 17.5%–50.7% in the 90-day window. This large, multi-tranche liquidation by the largest shareholder warrants attention given the company's path to profitability, the price action relative to the 52-week range, and the insider's mixed timing record at this ticker.

Redmile Group acquires 200,000 ADCT shares (4 tranches) for $609,000 on 2024-12-11; holder grows to 13.15M shares as stock down 39% in 90 days.

Redmile Group, a 10% owner, executed 4 separate purchases totaling 200,000 shares for $609,000.00 on 2024-12-11, increasing holdings from 12.95M to 13.15M shares (+1.5%). The purchases occurred at alternating prices of $2.28 and $3.81 per share, with a blended average price of $3.04—substantially above the current price of $1.89 (-64.3% from the 52-week high and down 39% over 90 days). At ADCT specifically, Redmile's prior 2 buys on 2024-07-01 showed positive 90-day returns (+9.6%), demonstrating a pattern of well-timed entry points at this ticker. However, the company faces significant headwinds: revenue contracted 66.9% year-over-year, the latest quarter generated only $18.5M in revenue against a net loss of $44.0M, and the market capitalization of $182.7M reflects material investor concern. The timing of this purchase—while the stock has already declined substantially from recent highs—occurs against deteriorating fundamentals, making this a critical test of whether Redmile's historical accuracy at ADCT will persist in a deteriorating business environment.

10% owner Redmile Group acquires 800,000 shares (800.0K) at $2.81 for $2,248,000; stock down -42.2% from 52-week high amid -66.9% revenue decline

Redmile Group, a 10% owner, made 2 separate purchases totaling 800,000 shares for $2,248,000.00 at $2.81 per share on July 1, 2024, increasing holdings to 13.00M shares. The timing coincides with significant deterioration in company fundamentals: ADC Therapeutics posted -$46.6M net income on $18.1M quarterly revenue, with annual revenue down -66.9% year-over-year. The current stock price of $3.06 sits -42.2% below the 52-week high and has declined -7.6% over the past 30 days and -35.0% over 90 days. Redmile's cross-ticker track record shows mixed predictive value (42.86% 90-day win rate on 7 prior buys with +6.6% average 90-day return), suggesting this purchase occurs in a context of material business deterioration rather than a contrarian positioning signal with historical accuracy.